Dr. Struble earned a PhD in Biophysics from Johns Hopkins University followed by a post-doctoral training at the National Institute of Standards and Technology, Gaithersburg, Md. She is a Research Pharmacologist in CBER, FDA, where she performs reviews of regulatory applications and mission-related research. Dr. Struble’s regulatory responsibilities include advice and evaluation of preclinical studies for plasma protein therapeutics, including hyperimmune globulin preparations for infectious disease indications.
As a research scientist, Dr. Struble investigates appropriate animal and in vitro models for assessing the safety and efficacy of antibody drugs during pregnancy. Her most recent work has been focused on therapies for Zika viral (ZIKV) infections.
Dr. Struble earned a PhD in Biophysics from Johns Hopkins University followed by a post-doctoral training at the National Institute of Standards and Technology, Gaithersburg, Md. She is a Research Pharmacologist in CBER, FDA, where she performs reviews of regulatory applications and mission-related research. Dr. Struble’s regulatory responsibilities include advice and evaluation of preclinical studies for plasma protein therapeutics, including hyperimmune globulin preparations for infectious disease indications.
As a research scientist, Dr. Struble investigates appropriate animal and in vitro models for assessing the safety and efficacy of antibody drugs during pregnancy. Her most recent work has been focused on therapies for Zika viral (ZIKV) infections.